Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
Status:
Withdrawn
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
AC480IV will be administered as a monotherapy and then in combination with docetaxel in
patients with locally advanced or metastatic solid tumors for whom there are no standard or
curative therapies available. It is designed to evaluate the safety and pharmacokinetic
parameters of AC480IV as monotherapy and also in combination with docetaxel under the
conditions of the study.